Hypoxia inducible factors in hepatocellular carcinoma

Chu Chen; Tao Lou

doi:10.18632/oncotarget.17358

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Hypoxia inducible factors in hepatocellular carcinoma

Chu Chen and Tao Lou _

PDF | HTML | How to cite

Oncotarget. 2017; 8:46691-46703. https://doi.org/10.18632/oncotarget.17358

Metrics: PDF 5503 views | HTML 11305 views | ?

Abstract

Chu Chen1, Tao Lou1

1Department of Internal Medicine, Fourth Affiliated Hospital of Zhejiang University, School of Medicine, Yiwu, 322000, Zhejiang, China

Correspondence to:

Tao Lou, email: [email protected]

Keywords: liver cancer, hepatoma, HIF, hypoxia, therapy

Received: February 13, 2017 Accepted: April 04, 2017 Published: April 21, 2017

ABSTRACT

Hepatocellular carcinoma is one of the most prevalent and lethal cancers with limited therapeutic options. Pathogenesis of this disease involves tumor hypoxia and the activation of hypoxia inducible factors. In this review, we describe the current understanding of hypoxia signaling pathway and summarize the expression, function and target genes of hypoxia inducible factors in hepatocellular carcinoma. We also highlight the recent progress in hypoxia-targeted therapeutic strategies in hepatocellular carcinoma and discuss further the future efforts for the study of hypoxia and/or hypoxia inducible factors in this deadly disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17358

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Hypoxia inducible factors in hepatocellular carcinoma

Abstract